Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives

Background: Surgery still represents the gold standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC). Neoadjuvant treatments (NAT), currently proposed for borderline and locally advanced PDACs, are gaining momentum even in resectable tumors due to the recent interesting concept...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Alessandro Coppola, Vincenzo La Vaccara, Tommaso Farolfi, Michele Fiore, Roberto Cammarata, Sara Ramella, Roberto Coppola, Damiano Caputo
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-08-01
סדרה:	Biomedicines
נושאים:	pancreatic ductal adenocarcinoma CA 19.9 neoadjuvant treatment upfront surgery early detection resectable pancreatic ductal adenocarcinoma
גישה מקוונת:	https://www.mdpi.com/2227-9059/10/9/2091
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!